SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity


Posted: 2021-11-13 20:00:00
Cell Immunol . 2021 Nov 7;371:104454. doi: 10.1016/j.cellimm.2021.104454. Online ahead of print. Affiliations Expand Affiliations 1 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea. 2 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Biochemistry, School of Life Sciences, Chungbuk National University, Cheongju, Republic of Korea. 3 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Functional Genomics, University of Science and Technology, Daejeon, Republic of Korea. 4 MRC Human Immunology Unit, Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, UK. Electronic address: hashem.koohy@rdm.ox.ac.uk. 5 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Functional Genomics, University of Science and Technology, Daejeon, Republic of Korea. Electronic address: haiyoung@kribb.re.kr. 6 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Functional Genomics, University of Science and Technology, Daejeon, Republic of Korea. Electronic address: ipchoi@kribb.re.kr. Item in Clipboard Hanna Kim et al. Cell Immunol. 2021. Show details Display options Display options Format Cell Immunol . 2021 Nov 7;371:104454. doi: 10.1016/j.cellimm.2021.104454. Online ahead of print. Affiliations 1 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea. 2 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Biochemistry, School of Life Sciences, Chungbuk National University, Cheongju, Republic of Korea. 3 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Functional Genomics, University of Science and Technology, Daejeon, Republic of Korea. 4 MRC Human Immunology Unit, Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, UK. Electronic address: hashem.koohy@rdm.ox.ac.uk. 5 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Functional Genomics, University of Science and Technology, Daejeon, Republic of Korea. Electronic address: haiyoung@kribb.re.kr. 6 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; Department of Functional Genomics, University of Science and Technology, Daejeon, Republic of Korea. Electronic address: ipchoi@kribb.re.kr. Item in Clipboard CiteDisplay options Display options Format Abstract Immune dysregulation is commonly observed in patients with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces severe lung inflammation and innate immune cell dysregulation. However, the precise interaction between SARS-CoV-2 and the innate immune system is currently unknown. To understand the interaction between SARS-CoV-2 and natural killer (NK) cells, several SARS-CoV-2 S protein peptides capable of binding to the NKG2D receptor were screened by in silico analysis. Among them, two peptides, cov1 and cov2, bound to NK cells and NKG2D receptors. These cov peptides increased NK cytotoxicity toward lung cancer cells, stimulated interferon gamma (IFN-γ) production by NK cells, and likely mediated these responses through the phosphorylation of Vav1, a key downstream-signaling molecule of NKG2D and NK activation genes. The direct interaction between SARS-CoV-2 and NK cells is a novel finding, and modulation of this interaction has potential clinical application as a therapeutic target for COVID-19. Keywords: Cytotoxicity; IFN-γ; NK; NKG2D; Peptide; SARS-Cov-2. Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
9月 06, 2021 バイオアソシエイツ

COVID-19ウイルスの広範な変異種から防御する抗体を発見。変異種間で変化の少ない受容体結合ドメイン(RBD)を標的としている。

現在のCOVID-19を引き起こすウイルスは、はるか昔の2019年12月に最初に人々を病気にしたウイルスと同じではない。現在流行している亜種の多くは、元のウイルスに基づいて開発された抗体ベースの治療薬の一部に部分的に耐性を持っている。パンデミックが続くと、必然的にさらに多くの亜種が発生し、耐性の問題は大きくなる一方だ。ワシントン大学医学部(セントルイス)の研究者らは、広範囲のウイルス亜種に対して低用量で高い保護効果を示す抗体を発見した。さらに、この抗体は、ウイルスの亜種間でほとんど違いのない部分に結合するため、この…

ゲスト 538人 と メンバー 6人 がオンラインです